Long-term data on ambulatory monitoring patches. Scientists from the Scripps Research Translational Institute and Johnson & Johnson have unveiled three-year study data for iRhythm Technologies' Zio wearable ambulatory monitoring patches at this year's American Heart Association Scientific Sessions. The mSToPS study examined 1,738 participants who were a mean age 73.7 years at the time of enrollment, and wore their patch for a median duration of 24.7 days.
Among these patients, 11.4% of those who were monitored with the patch were newly diagnosed with atrial fibrillation, as opposed to 7.7% of those in the control group. The group being monitored with the devices were less frequently hospitalized (12.9 per 100 person-years versus 18.9 per 100 person-years), and less often were hospitalized for the primary safety endpoint of bleeding (0.32 per 100 person-years versus 0.71 per 100 person-years).
"Active screening for AF, as part of a prospective, pragmatic, direct-to-participant, nationwide study, was associated with a significant improvement in clinical outcomes relative to standard-of-care controls, including a decrease in strokes and mortality," the researchers wrote in the study abstract.
Peloton appears to purchase Peerfit assets, staff. The Tampa Bay Business Journal reported that digital fitness benefits startup Peerfit had sold off assets and shipped off employees to an unnamed company.
Shortly after Exits & Outcomes connected the dots, noting that more than 30 employees from the software engineering side of the business had updated their LinkedIn accounts to reflect new positions at home workout company Peloton Interactive. Further, a recent SEC filing from Peloton disclosed two separate agreements to purchase "various developed technology, intellectual property and related assets for approximately $74.0 million," at least one of which would presumably be its dealings with Peerfit.
Neither company has released press releases or other formal announcements detailing these dealings.
One more health-tracking undergarment. Last week Nanowear announced that it received a 510(k) clearance for its SimpleSENSE "diagnostic undergarment and machine learning digital platform."
The gender neutral wearable monitors a range of cardiac, pulmonary and circulatory biomarkers, and according to the company is designed for telehealth or other types of remote monitoring. The company is commercializing the product with "select channel partners," and also said that it is conducting a clinical trial measuring the wearable's use in diagnosing worsening heart failure and COVID-19.
"SimpleSENSE marks the company's second FDA 510(k) clearance and follows Nanowear's strategy of continued data-driven differentiation in the connected-care and remote diagnostic market," Venk Varadan, cofounder and CEO of Nanowear, said in a statement. "In the face of the unexpected and unprecedented COVID-19 public health emergency, Nanowear began working collaboratively with FDA to evaluate a broadened indication for use for SimpleSENSE. Our platform can now efficiently serve the new need for remote diagnostics across primary care, acute illness and procedure, and chronic disease cases."
RxVantage buys onPoint Oncology. RxVantage, an app platform that connects providers teams educational materials or life science product representatives, has acquired oncology reimbursement data and analytics company onPoint Oncology for an undisclosed sum.
While onPoint Oncology will continue to operate as a wholly-owned subsidiary, RxVantage said that the deal will provide its oncology care team clients with in-app access to products such as focalPoint, which helps deliver timely and appropriate drug reimbursement, and intelliPoint, which focuses on identifying services creating value for life science customers.
"We are excited to welcome the onPoint team to the RxVantage family," Dan Gilman, RxVantage cofounder and CEO of RxVantage, said in a statement. "This partnership will further our mission to improve patient care and access to medications by empowering care teams with relevant and timely information and expertise. The onPoint team and their unique revenue-cycle data and reimbursement insights are respected across the industry and we look forward to bringing all of their capabilities to our customers."
Wearable sensors for clinical studies. Connected sensor company VivaLNK has kicked off a new package offering for clinical trials or other healthcare monitoring applications. Called the Vitals Data Service, it consists of the company's wearables, a customizable remote patient monitoring app and other format-flexible services for data access. The company is positioning the package as a turnkey service that can quickly and easily be implemented for in-person or remote use.
“The launch of the Vitals Data Service is an important step towards enabling the diverse and ever growing need to bring life-changing healthcare applications to market,” Jiang Li, CEO of VivaLNK, said in a statement. “The next generation of medical application and drug discovery is dependent on the ability to rapidly analyze continuous streams of data in order to understand a more complete picture of human physiology.”